Search Results

You are looking at 111 - 120 of 251 items for :

  • "Acute myeloid leukemia" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Allogeneic Hematopoietic Cell Transplantation for AML—A Missed Opportunity!

Margaret R. O'Donnell

. She was looking to identify ways to address the discordance between an extrapolation of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) combined with the SEER database of annual incidence of acute myeloid leukemia (AML) in patients

Full access

Hematopoietic Stem Cell Transplantation for Older Patients With Myelodysplastic Syndromes

H. Joachim Deeg and Marcos de Lima

outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation . J Clin Oncol 2007 ; 25 : 4246 – 4254 . 10. Sorror ML Storer B Sandmaier BM . Allogeneic hematopoietic cell

Full access

Financial Toxicity in Patients With Cancer: What a Tangled Web We Weave

Benyam Muluneh

after I finished speaking with the daughter (let’s call her Beth) of a patient who was starting an oral anticancer drug (venetoclax) for acute myeloid leukemia. I explained to Beth that although she was “told” the treatment would start next week, it all

Full access

Hematologic Malignancy: Who Cares in the End? A Retrospective Cohort Study of Markers of Quality End-of-Life Care

Briony Shaw, Catriona Parker, Stephen Opat, Jake Shortt, and Peter Poon

data and 229 were available for analysis ( Figure 1 ). Median age was 77 years (range, 24–99 years), with 35% female and 58% born outside Australia. Other demographics are described in Table 1 . Acute myeloid leukemia was the most frequent diagnosis

Full access

NCCN News

NCCN Guidelines. Presentations included treatment updates and patient case studies on: Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Chronic Myeloid Leukemia Diffuse Large B

Full access

NCCN News

as Vice President of Community and Support for an online virtual world. He holds a bachelor's degree in Computer and Information Sciences from the University of Massachusetts. In November 2010, Mr. Greene was diagnosed with acute myeloid leukemia

Full access

Myelodysplastic Syndromes, Version 2.2015

Peter L. Greenberg, Richard M. Stone, Rafael Bejar, John M. Bennett, Clara D. Bloomfield, Uma Borate, Carlos M. De Castro, H. Joachim Deeg, Amy E. DeZern, Amir T. Fathi, Olga Frankfurt, Karin Gaensler, Guillermo Garcia-Manero, Elizabeth A. Griffiths, David Head, Virginia Klimek, Rami Komrokji, Lisa A. Kujawski, Lori J. Maness, Margaret R. O’Donnell, Daniel A. Pollyea, Bart Scott, Paul J. Shami, Brady L. Stein, Peter Westervelt, Benton Wheeler, Dorothy A. Shead, and Courtney Smith

acute myeloid leukemia (AML) evolution. It should NCCN Guidelines Insights : Myelodysplastic Syndromes, Version 2.2015 Version 2.2015 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this

Full access

Characteristics Associated With Functional Changes During Systemic Cancer Treatments: A Systematic Review Focused on Older Adults

Kah Poh Loh, Vivian Lam, Katey Webber, Simran Padam, Mina S. Sedrak, Vivek Musinipally, Madison Grogan, Carolyn J. Presley, Janice Grandi, Chandrika Sanapala, Daniel A. Castillo, Grace DiGiovanni, Supriya G. Mohile, Louise C. Walter, and Melisa L. Wong

– 43 , 46 , 51 , 56 examined characteristics associated with functional improvement. Three articles 34 , 51 , 56 reporting results of a study of acute myeloid leukemia found that younger age was associated with greater improvement in timed chair

Full access

Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Jeffrey Crawford, Pamela Sue Becker, James O. Armitage, Douglas W. Blayney, Julio Chavez, Peter Curtin, Shira Dinner, Thomas Fynan, Ivana Gojo, Elizabeth A. Griffiths, Shannon Hough, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Mary Mably, Sudipto Mukherjee, Shiven Patel, Lia E. Perez, Adam Poust, Raajit Rampal, Vivek Roy, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, Mahsa Talbott, Saroj Vadhan-Raj, Sumithira Vasu, Martha Wadleigh, Peter Westervelt, Jennifer L. Burns, and Lenora Pluchino

. Additional indications for filgrastim and filgrastim-sndz include treatment for patients with acute myeloid leukemia (AML) receiving induction or consolidation chemotherapy, patients with cancer receiving bone marrow transplant, patients undergoing peripheral

Full access

A Patient Risk Model of Chemotherapy-Induced Febrile Neutropenia: Lessons Learned From the ANC Study Group

Gary H. Lyman and Marek S. Poniewierski

developing acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) in patients treated with MGFs. In an analysis of data from the SEER-Medicare linked files, Hershman et al 28 observed a doubling of the risk of subsequent AML or MDS from 0.7% to 1